BIOHELIX-I Bare Metal Stent Study

NCT ID: NCT01612767

Last Updated: 2018-09-28

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2/PHASE3
• Total Enrollment: 329 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-11-30
• Study Completion Date: 2017-11-30

Brief Summary

The purpose of this study is to demonstrate the safety and efficacy of the investigational BIOTRONIK PRO-Kinetic Energy stent in subjects with atherosclerotic disease of native coronary arteries.

Conditions

Coronary Arteries Disease

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Pro-Kinetic Energy Stent

Group Type: EXPERIMENTAL

PRO-Kinetic Energy Stent

Intervention Type: DEVICE

Coronary artery stent implant

Interventions

PRO-Kinetic Energy Stent

Coronary artery stent implant

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Age ≥ 18 years
• Willingness to comply with study follow-up requirements
• Candidate for a percutaneous coronary intervention (PCI) procedure
• Candidate for coronary artery bypass graft surgery
• Documented evidence of stable or unstable angina pectoris or positive functional ischemia study (e.g. exercise treadmill test, thallium stress test, SPECT, stress echocardiogram or cardiac CT) Stable angina pectoris is defined as a documented Canadian Cardiovascular Society Classification of I, II, III or IV Unstable angina pectoris is defined as a documented Braunwald Classification of B & C, I, II, III
• Written informed consent

For a subject to receive an investigational stent, the following procedure-related criteria must be met:

• De novo or restenotic lesion in a native coronary artery; restenotic lesions must have been previously treated with only standard percutaneous transluminal coronary angioplasty (PTCA) (treatment must be > 12 months prior to the index procedure)
• Target lesion must be in a major coronary artery (target vessel). The target vessel includes the entire territory of the left anterior descending artery, left circumflex artery or right coronary artery and any major side branch of the artery.
• A maximum of one target lesion and one non-target lesion may be treated per subject. The lesions must be located in separate coronary arteries, with treatment of the non-target lesion occurring first using commercially available therapy (with exception of brachytherapy).
• Lesions may be one solid lesion or a series of multiple, smaller lesions to be treated as one lesion
• Target lesion must be treatable with a single investigational stent; an additional stent may be used when treating a vessel dissection or another similar intra-procedure complication (use of investigational stent preferred)
• Angiographic evidence of ≥ 50% and < 100% stenosis (by operator visual estimate) with a TIMI flow > 1
• Target lesion length of ≤ 31 mm by operator visual estimate
• Target vessel reference diameter of 2.25 mm to 4.0 mm by operator visual estimate

Exclusion Criteria

• Baseline LVEF of < 30%; LVEF may be measured and assessed by standard-of-care echocardiography procedures within 90 days of the index procedure or by a left ventriculogram prior to the index procedure (operator visual assessment).
• PCI in any vessel 30 days prior to the index procedure or planned for within 30 days after the index procedure
• Stroke or transient ischemic attack within the last 6 months prior to enrollment
• Intolerance to contrast agents that cannot be medically managed and/or intolerance to antiplatelet, anticoagulant or thrombolytic medications
• Refusal of blood transfusions
• Any other medical condition, that in the opinion of the investigator, poses an unacceptable risk for implant of a stent according to the study indications
• Pregnant, planning to become pregnant or nursing during the course of the study. Women of child-bearing potential must have a negative blood pregnancy (beta hCG) test. Female subjects who are surgically sterile or post-menopausal are exempt from having a pregnancy test.
• Known allergy to L-605 CoCr alloy (cobalt, chromium, tungsten and nickel) or amorphous silicon carbide
• Life expectancy of less than one year
• Participation in any other clinical investigational device or drug study.
• Subjects may be concurrently enrolled in a post-market study, as long as the post-market study device, drug or protocol does not interfere with the investigational treatment or protocol of this study.

For a subject to receive an investigational stent the following procedure-related criteria must not be present:

• Documented diagnosis of an acute MI within 72 hours of the index procedure and an elevation of Troponin or creatine kinase-MB (CKMB) above the URL (CKMB measurement is not required if CK is normal) at the time of the index procedure (99th percentile of the individual investigative site's normal reference population)

• For subjects with stable angina and elevated Troponin, CKMB <99% URL is required
• ECG changes consistent with an acute MI within 72 hours of the index procedure. ECG changes consistent with an acute MI include:

> 1 mm ST segment elevation or depression in consecutive leads New left bundle branch block (LBBB) Development of pathological Q-waves in two contiguous leads of the electrocardiogram (ECG)

• Acute coronary syndrome with baseline Troponin > 99% URL
• INR ≥ 1.6
• Concomitant renal failure with serum creatinine level > 2.5 mg/dL
• Unresolved neutropenia (white blood cell count < 3,000 / µL), thrombocytopenia (platelet count < 100,000 / µL) or thrombocytosis (platelet count > 700,000 / µL)
• Unprotected left main coronary artery disease (CAD) (> 50% diameter stenosis by operator visual estimate)
• Target vessel has been treated with any PCI procedure (e.g. PTCA, stent, cutting balloon, atherectomy, etc.) within 12 months prior to the index procedure
• Target lesion has been treated with a stent, cutting balloon or atherectomy any time prior to the index procedure or has been treated with PTCA within 12 months prior to the index procedure
• Target vessel treated with brachytherapy anytime prior to index procedure
• Planned PCI in the target vessel within 9 months after the index procedure
• Target vessel has a non-target lesion with a > 50% stenosis that requires treatment during the index procedure
• Lesions preventing distal perfusion (TIMI flow 0 and 1) prior to wire crossing
• Target lesion is in the left main coronary artery or within 2 mm of the origin of the left anterior descending artery or left circumflex artery by operator visual estimate
• Target lesion is located within a saphenous vein graft or arterial graft
• Target lesion involves a bifurcation - lesion is located in a major coronary artery and involves a side branch with a diameter > 2 mm (by operator visual estimate)
• Presence of a complication following pre-dilatation of target lesion
• Presence of a complication following treatment of a non-target lesion (if applicable)
• Presence of a target vessel/lesion that has excessive tortuousity/angulation or is severely calcified preventing complete inflation of an angioplasty balloon
• Angiographic evidence of thrombus within the target lesion
• Target lesion is located within an aneurysm or associated with an aneurysm in the vessel segment either proximal or distal to the target lesion
• Use of cutting balloons, atherectomy or ablative devices immediately prior to investigational stent placement

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Biotronik, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Saurabh Gupta, MD

Role: PRINCIPAL_INVESTIGATOR

Oregon Health and Science University

Locations

Phoenix, Arizona, United States

Concord, California, United States

Mission Viejo, California, United States

Danbury, Connecticut, United States

New Haven, Connecticut, United States

Washington D.C., District of Columbia, United States

Gainesville, Georgia, United States

Indianapolis, Indiana, United States

Iowa City, Iowa, United States

Lafayette, Louisiana, United States

Lewiston, Maine, United States

Takoma Park, Maryland, United States

Kansas City, Missouri, United States

Springfield, Missouri, United States

Newark, New Jersey, United States

New York, New York, United States

New York, New York, United States

Poughkeepsie, New York, United States

Gastonia, North Carolina, United States

High Point, North Carolina, United States

Columbus, Ohio, United States

Portland, Oregon, United States

Anderson, South Carolina, United States

Greenville, South Carolina, United States

Amarillo, Texas, United States

McKinney, Texas, United States

Tyler, Texas, United States

Mechanicsville, Virginia, United States

Medellín, , Colombia

Bad Segeberg, , Germany

Essen, , Germany

Ludwigshafen, , Germany

Riga, , Latvia

Amsterdam, , Netherlands

Eindhoven, , Netherlands

Countries

United States; Colombia; Germany; Latvia; Netherlands

Other Identifiers

G110147

Identifier Type: -

Identifier Source: org_study_id